NNC0194 0499
Alternative Names: NN 9500; NN9499; NNC-0194-0499Latest Information Update: 28 Apr 2026
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Drug withdrawal therapies; Hepatoprotectants; Obesity therapies
- Mechanism of Action Fibroblast growth factor receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholic liver disorders; Non-alcoholic steatohepatitis
- Phase I Type 1 diabetes mellitus
- No development reported Non-alcoholic fatty liver disease; Obesity
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(Combination therapy, In volunteers) in Canada (SC, Injection)
- 28 Apr 2026 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(Monotherapy, In volunteers) in Canada (SC, Injection)
- 28 Mar 2026 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease(In volunteers) in China (SC, Injection)